New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
07:03 EDTCGENCompugen reports Q1 EPS (4c), consensus (10c)
Reports Q1 revenue $2.13, consensus $1.84M. The company said, "Cost of revenues for Q1 were $757K, compared with $150K for the comparable period in FY13. This increase reflects, in large part, research and development expenses attributed to our ongoing collaboration agreements."
News For CGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 14, 2014
14:03 EDTCGENCompugen achieves second preclinical milestone under Bayer cancer collaboration
Compugen (CGEN) disclosed that it has achieved a second milestone in its cancer immunotherapy collaboration it entered last year with Bayer HealthCare (BAYRY). The collaboration provides for the research, development, and commercialization of antibody-based cancer therapeutics against two novel Compugen-discovered immune checkpoint regulators. The milestone being announced relates to the second preclinical milestone for one of the checkpoint protein candidates.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use